MorphoSys AG will receive a milestone payment from Centocor Ortho Biotech, Inc. for the initiation of a Phase I trial using a HuCAL-derived, fully human antibody in the therapeutic area of inflammation.

"The advancement of a new HuCAL antibody into human clinical trials is an important step forward for MorphoSys," commented Dr. Simon Moroney, chief executive officer of MorphoSys. "Progress in the development of innovative biopharmaceutical agents by our partners is a key driver of our company's growth."

This is the second HuCAL antibody program derived from the companies' collaboration to enter clinical trials. With the new study, Centocor Ortho Biotech will be running three clinical trials of HuCAL antibodies.

News from our sister sites